Anti-mouse/rat MHC Class II (I-Ek/RT1-D) (Clone 14-4-4S (HB-32)) – Purified in vivo PLATINUM™ Functional Grade
Anti-mouse/rat MHC Class II (I-Ek/RT1-D) (Clone 14-4-4S (HB-32)) – Purified in vivo PLATINUM™ Functional Grade
Product No.: H450
- -
- -
Clone 14-4-4S Target MHC Class II (I-Ek/RT1-D) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names I-Ek, MHC class II Isotype Mouse IgG2a k Applications FA , FC , IHC , IP |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse ⋅ Rat Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen C3H mouse skin graft and splenocytes Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FA, FC, IHC, IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity 14-4-4S (HB-32) activity is directed against mouse MHC Class II alloantigen I-Ek
and rat MHC Class II alloantigen RT1-D. In mouse, 14-4-4S cross-reacts with H-2k, H-2d, H-2p,
and H-2r and is specific to Ia.7 in the Ia chart. 14-4-4S also recognizes a cell surface marker on
hamster B lymphocytes. Background H-2, the murine major histocompatibility complex (MHC), is composed of a diverse group of
antigens divided into class I and II proteins that function in immune response1. Class II molecules, also known as Ia antigens, regulate recognition of foreign antigens on the surfaces of antigen presenting cells and play a major role in the mixed lymphocyte response2. Mice have two class II isotypes, I-A and I-E, each of which is a glycoprotein composed of an ⍺ and β Subunit. 14-4-4S was generated by immunizing C3H.SW mice with spleen cells from C3H mice3. The resulting spleen cells were then fused with Sp2/0-Ag14 myeloma cells for hybridoma generation. Further studies have found that whole 14-4-4S antibody and F(ab’)2 fragments block RT1-D-restricted Ag presentation as well as activation of an I-Eʹ-restricted T cell hybridoma in vitro4. Additionally, because 14-4-4S recognizes hamster B cells, 14-4-4S can be used in hamster to deplete B cells and enrich for T cells via flow cytometry5 or by removing adherent B lymphocytes in immunoglobulin-coated tissue culture dishes6. Antigen Distribution I-Ek and RT1-D are expressed primarily on the surface of B lymphocytes,
antigen-presenting cells, macrophages, dendritic cells, and a subset of T cells. Ligand/Receptor CD3/TCR, CD4 NCBI Gene Bank ID UniProt.org Research Area Immunology References & Citations1 Yoshida R. Adv Immunol. 124:207-247. 2014. 2 Spencer JS, Kubo RT. J Exp Med. 169(3):625-460. 1989. 3 Ozato K, Mayer N, Sachs DH. J Immunol. 124(2):533-540. 1980. 4 Haag S, Tuncel J, Thordardottir S, et al. J Immunol. 194(6):2539-2350. 2015. 5 Liu H, Steiner BM, Alder JD, et al. Infect Immun. 58(6):1685-1690. 1990. 6 Lim LC, England DM, DuChateau BK, et al. Infect Immun. 63(4):1400-1408. 1995. 7 Shih FF, Racz J, Allen PM. J Immunol. 176(6):3438-3448. 2006. 8 Epstein SL, Ozato K, Bluestone JA, et al. J Exp Med. 154(2):397-409. 1981. 9 Turkewitz AP, Sullivan CP, Mescher MF. Mol Immunol. 20(11):1139-1147. 1983. 10 Maloy WL, Ozato K, Sachs DH, et al. Mol Immunol. 23(3):263-269. 1986. 11 Farr A, DeRoos PC, Eastman S, et al. Eur J Immunol. 26(12):3185-3193. 1996. 12 Desmet C, Gosset P, Pajak B, et al. J Immunol. 173(9):5766-5775. 2004. 13 Holmberg D, Forsgren S, Forni L, et al. Proc Natl Acad Sci U S A. 81(10):3175-3179. 1984. 14 Isobe M, Narula J, Southern JF, et al. Circulation. 85(2):738-746. 1992. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
H452 | |
H453 | |
H454 | |
H450 | |
H451 |
